MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
04 Mai 2023 - 2:05PM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the
signing of a strategic platform license (SPL) with Walking Fish
Therapeutics, Inc. a biotechnology company that is rapidly
advancing B cell-based therapeutics.
Under the terms of the agreement, Walking Fish
obtains non-exclusive clinical and commercial rights to use
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In
return, MaxCyte is entitled to receive platform licensing fees,
clinical milestone payments and sales-based payments.
“We are delighted to partner with Walking Fish
to help advance their B cell platform and support their innovative
approach to develop novel therapies for the treatment of serious
diseases,” said Doug Doerfler, President and CEO of
MaxCyte.
Walking Fish is a privately held biotechnology
company discovering and developing innovative therapeutics that
harness the power of B cells as protein factories and immune
modulators. Walking Fish has created a broad technology platform
addressing enzyme replacement therapies, oncology, autoimmune
disease, and recombinant antibody production. Walking Fish’s first
program, WFX-001 employs B cells as protein factories to generate a
deficient enzyme in Fabry disease.
MaxCyte’s ExPERT™ instrument portfolio is the
next generation of leading, clinically-validated electroporation
technology for complex and scalable cell engineering. By delivering
high transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Walking Fish is MaxCyte’s 20th strategic
partnership overall, each of which generates pre-commercial
milestone revenue and the vast majority of which include
sales-based payments.
About MaxCyte
At MaxCyte, we pursue cell engineering
excellence to maximize the potential of cells to improve patients’
lives. We have spent more than 20 years honing our expertise by
building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today’s processes to
innovate tomorrow’s solutions. Our ExPERT™ platform, which is based
on our Flow Electroporation technology, has been designed to
support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as technical and
regulatory support, we aim to guide them on their journey to
transform human health. Learn more at maxcyte.com and follow us on
Twitter and LinkedIn.
About Walking Fish
Therapeutics
A leader in B cell medicines, Walking Fish
Therapeutics discovers and develops innovative therapeutics that
harness the power of B cells as protein factories and immune
modulators to treat has made critical advances in engineering
technologies to rapidly advance cell-based therapeutics to treat
serious diseases, concentrating on oncology, rare diseases,
oncology, autoimmune disease, and other life-threatening
conditions. For more information and important updates, please
visit walkingfishtx.com.
MaxCyte Contacts:
US IR AdviserGilmartin GroupDavid Deuchler,
CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Maxcyte (LSE:MXCN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024